Traduction de «incremental cost-effectiveness ratio – ratio cout » (Français → Néerlandais) :

Conformément aux standards du NICE, les résultats ont été relativement défavorables et " le Comité a conclu que l'ICER (incremental cost-effectiveness ratio – ratio cout efficacité incrémental) le plus plausible du bevacizumab plus paclitaxel versus du paclitaxel toutes les semaines se situait entre £110,000 et £259,000 par QALY gagné”.
Volgens de NICE normen waren de resultaten relatief ongunstig en " de Commissie besloot dat de meest plausibele ICER (incremental cost-effectiveness ratio - incrementele kosteneffectiviteitsratio) voor bevacizumab in combinatie met paclitaxel ten opzichte van wekelijkse paclitaxel tussen £110,000 en £259,000 per gewonnen QALY schommelde" .

Dans les cas où une intervention débouche sur des résultats plus favorables pour la santé mais à un coût supérieur en comparaison avec la meilleure intervention alternative visant la même affection, un rapport coût-efficacité différentiel (Incremental Cost-Effectiveness Ratio, ICER) est calculé.
Wanneer een interventie betere resultaten voor de gezondheid oplevert maar meer kost, kan de kosteneffectiviteit berekend worden, uitgedrukt als een Incremental Cost-Effectiveness Ratio (ICER).

Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.